Sophie Lemire-Brachat and Naisha Shah at ARDD2026: APEx (Aging and Physical Exercise)

Sophie Lemire-Brachat and Naisha Shah at ARDD2026: APEx (Aging and Physical Exercise)

Title history
  • Sophie Lemire-Brachat and Naisha Shah at ARDD2026: APEx (Aging and Physical Exercise) — observed on 20261110-2124 UTC (YouTube)
🎙 Sophie Lemire-Brachat (Novartis) and Naisha Shah (BioAge) 👥 9K 📅 November 10, 2026 ⏱ 18 min 👁 8 📄 original study 🧭 2026-11-10
Available in: English (current) Français

Keywords

agingdrug discoveryexerciselongitudinal cohortsproteomics

Summary

The presentation by Sophie Lemire-Brachat (Novartis) and Naisha Shah (BioAge) at ARDD2026 introduces a collaborative platform called APEx (Aging and Physical Exercise) designed to discover novel therapeutic targets by integrating longitudinal human data with exercise biology. The speakers emphasize that aging is a progressive temporal decline in physical function, requiring longitudinal datasets to capture the underlying molecular trajectories. They highlight the value of combining decades of serial-time-point data from aging cohorts with detailed phenotyping, such as VO2 max and grip strength, to identify early biomarkers and mechanisms of resilience. Using examples like heart failure and Alzheimer’s disease, they show how serial proteomics can detect disease-related molecular changes many years before clinical diagnosis. They also discuss the study of ‘superheroes’ – individuals with high genetic risk who remain healthy – to uncover protective mechanisms. The platform incorporates a knowledge graph connecting proteomic, genetic, and phenotypic data, with evidence-based ranking to support target selection. They conclude by showing a specific target profile that changes with age, predicts mortality, and spans multiple disease indications, illustrating the platform’s potential.

175 words

Critical Evaluation

Value of the Information & Strength of the Argument

The value of this presentation lies in its emphasis on leveraging longitudinal human data to capture the temporal dynamics of aging and disease progression, which is a relatively underexplored approach compared to cross-sectional studies. The argumentation is coherent: they build a logical case that integrating exercise physiology, longitudinal cohorts, and proteomics can reveal early molecular changes and resilience mechanisms. The examples provided, such as detecting heart failure biomarkers years before diagnosis and studying Alzheimer’s-resistant individuals, illustrate the utility of the platform. However, the argumentation is largely based on their own internal data and preliminary results, without detailed statistical rigor or external validation. The strength of the reasoning is moderate, but the concept is innovative and well-motivated.

Scientific Rigor, Source Quality, Title Accuracy

The talk is a conference presentation of original work, not a peer-reviewed publication. The speakers reference prior work from their own groups (Fiona Marshall’s talk, existing longitudinal cohorts) and mention the use of established biomarkers such as NT-proBNP and P-tau217. No external literature is cited. The description provides links to the ARDD official website and LinkedIn, which serve as primary sources for the conference organization. The title is accurate and not exaggerated. Overall, the scientific rigor is moderate: the data are plausible but lack the transparency and detail expected of formal studies. The lack of external source citation is a limitation, but the presentation is consistent with a conference talk.

241 words

Title / Content Match

The title accurately reflects the content, which is a joint presentation on the APEx initiative combining aging and physical activity data for target discovery.

Quality & Reliability

7/10

The talk presents preliminary results and a platform description, but lacks detailed methodological transparency, external validation, and peer review. Claims are plausible but require supporting data.

Key Moments

Cited Sources

  • ARDD Official Website — Main conference website providing information about ARDD and its organization.
  • ARDD LinkedIn — LinkedIn page of ARDD for updates and networking.

Contribution & Novelties

The main novelty is the integration of longitudinal human cohorts with exercise biology to identify drug targets that mimic the protective effects of physical activity. The APEx platform combines serial proteomics, genetics, and deep phenotyping to detect early disease signals and resilience mechanisms, which is a distinctive approach. It also leverages a knowledge graph for evidence-based target ranking.

Pour aller plus loin :

  • Longitudinal study — Relevance: Core methodology discussed in the talk; longitudinal data are essential for capturing aging trajectories.
  • Protein–protein interaction — Relevance: The talk emphasizes network-based analysis and knowledge graphs integrating protein interactions.
  • Drug discovery — Relevance: The ultimate goal of the platform is to discover novel therapeutic targets.

112 words

Radar Profile

The profile shows strong scores in information quantity and technical level, but lower reliability and quality, reflecting a presentation rich in data and expert insight yet lacking formal peer review and external validation.

Reliability 6/10